GlassScriptPhysician profile
Christopher Jason Guinn
NPI 1144858358
$9,748.21
in general payments reported to CMS, 2019-2025
27 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.81 · 2023: $653 · 2024: $7,071 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,971 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,420 · Travel and Lodging: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,970.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,420.00 |
| Travel and Lodging | $1,302.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $4,733.52 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $576.60 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $545.67 | 2023-2025 | Airsupra, Breztri |
| Intuitive Surgical, INC. | $508.75 | 2024 | |
| Novo Nordisk INC | $507.15 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $451.06 | 2022-2025 | |
| Lilly USA, LLC | $365.89 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $356.18 | 2023-2025 | |
| Pfizer INC. | $353.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $300.59 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Corium, LLC | $179.40 | 2024-2025 | Azstarys |
| Astellas Pharma US INC | $132.26 | 2025 | Veozah |
| Abbott Laboratories | $121.80 | 2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $109.80 | 2023-2025 | Rexulti |
| Edwards Lifesciences Corporation | $94.86 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $91.91 | 2024 | |
| Exact Sciences Corporation | $65.97 | 2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $40.79 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $34.08 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $29.47 | 2025 | Zoryve |
| Amgen INC. | $29.01 | 2025 | Otezla, Repatha |
| Biogen, INC. | $23.44 | 2024 | Skyclarys |
| Dexcom, INC. | $22.42 | 2024 | Dexcom G6 Transmitter |
| Pharmacosmos Therapeutics INC. | $22.36 | 2023 | Monoferric |
| Mylan Specialty L.P. | $21.57 | 2024 | Yupelri |
| Currax Pharmaceuticals LLC | $16.77 | 2024 | Onzetra Xsail, Contrave |
| Sanofi-Aventis U.S. LLC | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Guinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.